Vimarsana
Biggest News Aggregation in the World

Page 5 - Dana Walker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dana Walker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dana Walker Today - Breaking & Trending Today

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary... - Vimarsana News

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...

Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy Combination of...

Nivolumab Plus Ipilimumab Improves PFS in Newly Diagnosed Metastatic Colorectal Cancer - Vimarsana News

Nivolumab Plus Ipilimumab Improves PFS in Newly Diagnosed Metastatic Colorectal Cancer

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

FDA Grants Priority Review to Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma - Vimarsana News

FDA Grants Priority Review to Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma

The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.

FDA Accepts Priority Review for Opdivo Plus Chemo in Bladder Cancer Subtype - Vimarsana News

FDA Accepts Priority Review for Opdivo Plus Chemo in Bladder Cancer Subtype

The FDA accepted a priority review for the supplemental Biologics License Application of Opdivo with chemotherapy for untreated patients with unresectable or metastatic bladder cancer.

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients - Vimarsana News

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients

PRINCETON - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for Opdivo in combination with...